Metsera, Inc. - Common Stock (MTSR)

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Pfizer's own GLP-1 drug candidate failed earlier this year -- so it's buying someone else's.

Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

The deal follows two high-profile failures for Pfizer, which is trying to broaden its small pipeline in weight loss.

Pfizer will buy Metsera for $4.9 billion plus milestone payments, adding incretin, amylin, and oral obesity drug candidates to its pipeline.

The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs.

The upfront purchase price of $47.50 per share implies a premium of 43% from Metsera’s closing share price on Friday.

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.